These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28741800)

  • 1. Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns-an Alternative Viewpoint.
    Irwin AN; Herink MC
    Pharmacotherapy; 2017 Oct; 37(10):e109-e111. PubMed ID: 28741800
    [No Abstract]   [Full Text] [Related]  

  • 2. Eteplirsen in the treatment of Duchenne muscular dystrophy.
    Lim KR; Maruyama R; Yokota T
    Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
    Charleston JS; Schnell FJ; Dworzak J; Donoghue C; Lewis S; Chen L; Young GD; Milici AJ; Voss J; DeAlwis U; Wentworth B; Rodino-Klapac LR; Sahenk Z; Frank D; Mendell JR
    Neurology; 2018 Jun; 90(24):e2146-e2154. PubMed ID: 29752304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
    McDonald CM; Shieh PB; Abdel-Hamid HZ; Connolly AM; Ciafaloni E; Wagner KR; Goemans N; Mercuri E; Khan N; Koenig E; Malhotra J; Zhang W; Han B; Mendell JR;
    J Neuromuscul Dis; 2021; 8(6):989-1001. PubMed ID: 34120909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eteplirsen: First Global Approval.
    Syed YY
    Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
    Aartsma-Rus A; Krieg AM
    Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping.
    Mercuri E; Seferian AM; Servais L; Deconinck N; Stevenson H; Ni X; Zhang W; East L; Yonren S; Muntoni F;
    Neuromuscul Disord; 2023 Jun; 33(6):476-483. PubMed ID: 37207382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.
    Khan N; Eliopoulos H; Han L; Kinane TB; Lowes LP; Mendell JR; Gordish-Dressman H; Henricson EK; McDonald CM;
    J Neuromuscul Dis; 2019; 6(2):213-225. PubMed ID: 30856119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 11. Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line.
    Dowling JJ
    Nat Rev Neurol; 2016 Dec; 12(12):675-676. PubMed ID: 27857122
    [No Abstract]   [Full Text] [Related]  

  • 12. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy.
    Alfano LN; Charleston JS; Connolly AM; Cripe L; Donoghue C; Dracker R; Dworzak J; Eliopoulos H; Frank DE; Lewis S; Lucas K; Lynch J; Milici AJ; Flynt A; Naughton E; Rodino-Klapac LR; Sahenk Z; Schnell FJ; Young GD; Mendell JR; Lowes LP
    Medicine (Baltimore); 2019 Jun; 98(26):e15858. PubMed ID: 31261494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eteplirsen for the treatment of Duchenne muscular dystrophy.
    Mendell JR; Rodino-Klapac LR; Sahenk Z; Roush K; Bird L; Lowes LP; Alfano L; Gomez AM; Lewis S; Kota J; Malik V; Shontz K; Walker CM; Flanigan KM; Corridore M; Kean JR; Allen HD; Shilling C; Melia KR; Sazani P; Saoud JB; Kaye EM;
    Ann Neurol; 2013 Nov; 74(5):637-47. PubMed ID: 23907995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon skipping therapy for Duchenne muscular dystrophy.
    Kole R; Krieg AM
    Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eteplirsen (Exondys 51) for duchenne muscular dystrophy.
    Med Lett Drugs Ther; 2016 Nov; 58(1507):145-146. PubMed ID: 27805575
    [No Abstract]   [Full Text] [Related]  

  • 17. Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice.
    Stein CA
    Mol Ther; 2016 Nov; 24(11):1884-1885. PubMed ID: 27916994
    [No Abstract]   [Full Text] [Related]  

  • 18. Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis.
    Randeree L; Eslick GD
    J Clin Neurosci; 2018 Mar; 49():1-6. PubMed ID: 29254734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why dystrophin quantification is key in the eteplirsen saga.
    Aartsma-Rus A; Arechavala-Gomeza V
    Nat Rev Neurol; 2018 Aug; 14(8):454-456. PubMed ID: 29967362
    [No Abstract]   [Full Text] [Related]  

  • 20. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.